Clever, Personable, and Unconventional: F-star Therapeutics Strikes a Deal with Takeda for Next-Gen Immuno-Oncology Antibody
F-star Therapeutics Announces a License Agreement with Takeda for a Novel Next-Generation Bispecific Immuno-Oncology Program CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company specializing in bispecifics in immunotherapy, has revealed a new partnership with Takeda F-star Therapeutics, Inc. is a groundbreaking company that…